Company intelligence / Profile preview
Simcere Pharmaceutical Group
Nanjing, Jiangsu, Chinaen.simcere.com ↗
- Ownership
- Public · 2096
- Employees
- ~6412
- Development stage
- Other
01
Overview
Simcere has developed and launched 3 category I innovative pharmaceuticals in China. Recent clinical developments include SIM0500 (Phase 1 for multiple myeloma), SIM0508 (received clinical trial approval), and XIANNUOXIN (approved in China). The company has over 150 clinical trials.
- Therapeutic areas
- CardiovascularRheumatologyImmunologyDermatologyOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesmonoclonal antibodiestrispecific antibodies
- Industry
- Biotech
02
Drug pipeline
106 assets105 more assets in the full pipeline.
03
Partnerships
AbbVieConnect BiopharmaLynk PharmaceuticalsAlmirallDaiichi SankyoShenzhen TargetRxMass General Brigham
04
Financials
- Market cap
- $3.7B
- Total revenue
- $1.2B
- Enterprise value
- $3.4B
Beyond the preview
Go deeper on Simcere Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simcere Pharmaceutical Group.